# ClinicalTrials.gov record NCT05162768

> PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct05162768-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05162768-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05162768-elamipretide-v1.json
- Content SHA-256: `949c909b61837885b0346ca6cde6b740c610b963712fa0745a3161d9da750aa0`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05162768 ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

## Sources

<a id="source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd"></a>
- **ClinicalTrials.gov record NCT05162768 · retained source version 2025-10-24:7e45e33488fdf229c542f8cf1d0fd1a6e6c1a5f43c04d1eb153e8ada606be685** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05162768) (`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05162768." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05162768-elamipretide-v1.json SHA-256: 949c909b61837885b0346ca6cde6b740c610b963712fa0745a3161d9da750aa0.